BioSpace News Archive

Pharm Country

Galera Adopts Limited Duration Stockholder Rights Agreement - May 03, 2024

Galera Therapeutics, Inc. announced that its Board of Directors has unanimously resolved to adopt a limited duration stockholder rights agreement to protect stockholder interests.

May 3, 2024
·
4 min read
Drug Development

HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease

HanAll Biopharma Co., Ltd. (KRX: 009420. KS) announced the initiation of a Phase III VELOS-4 trial evaluating the efficacy and safety of tanfanercept, a novel, topical anti-inflammatory treatment in participants with moderate to severe dry eye disease (DED).

May 3, 2024
·
7 min read
Business

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024.

May 3, 2024
·
1 min read
Business

Fulgent Reports First Quarter 2024 Financial Results

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2024.

May 3, 2024
·
13 min read
Deals

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 3, 2024

Kura Oncology, Inc today announced that on May 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 67,950 shares of common stock to six (6) new employees.

May 3, 2024
·
2 min read
Genetown

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

Ocular Therapeutix, Inc. announced multiple presentations at the Ophthalmology Innovation Source (OIS) Retina 2024 (May 4th) and the Association for Research in Vision and Ophthalmology (ARVO) 2024 meetings (May 5-9th) being held in Seattle, Washington.

May 3, 2024
·
7 min read
Business

MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call

MacroGenics, Inc. today announced that the Company will release its financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024.

May 3, 2024
·
1 min read
Business

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024.

May 3, 2024
·
1 min read
BioMidwest

Sun Nuclear Showcases New Quality Management Solutions for Radiation Therapy Teams and Workflows at ESTRO Annual Meeting

Sun Nuclear, a Mirion Medical company, will feature new and enhanced solutions for better Quality Management at the ESTRO Annual Meeting, May 3-6, in Glasgow, Scotland.

May 3, 2024
·
4 min read
Business

Immuron Director Resignation - May 03, 2024

Immuron Limited, an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou has resigned from his position as Non-Executive Director effective to focus on his other business interests.

May 3, 2024
·
7 min read